Ligand(LGND) - 2025 Q1 - Quarterly Results

Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 8, 2025 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss this announcement ...